Report cover image

Global Humanized Bispecific Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 198 Pages
SKU # APRC20276829

Description

Summary

According to APO Research, The global Humanized Bispecific Antibodies market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Humanized Bispecific Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Humanized Bispecific Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Humanized Bispecific Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Humanized Bispecific Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Humanized Bispecific Antibodies include Tuowei Biotechnology, Genor Biopharma, Hansoh Pharmaceutical, Doma Biopharmaceutical, Dizal Pharma, Betta Pharmaceuticals, Biocytogen Co., Ltd., EpimAb Biotherapeutics and Allist, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Humanized Bispecific Antibodies, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Humanized Bispecific Antibodies, also provides the sales of main regions and countries. Of the upcoming market potential for Humanized Bispecific Antibodies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Humanized Bispecific Antibodies sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Humanized Bispecific Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Humanized Bispecific Antibodies sales, projected growth trends, production technology, application and end-user industry.

Humanized Bispecific Antibodies Segment by Company

Tuowei Biotechnology
Genor Biopharma
Hansoh Pharmaceutical
Doma Biopharmaceutical
Dizal Pharma
Betta Pharmaceuticals
Biocytogen Co., Ltd.
EpimAb Biotherapeutics
Allist
MacroGenics
Johnson & Johnson
AstraZeneca
Humanized Bispecific Antibodies Segment by Type

IgG-like Double Antibody
Fragmented Dual Antibody (FAD)
Others
Humanized Bispecific Antibodies Segment by Application

Infectious Disease Control
Immune Disease Treatment
Oncology Treatment
Others
Humanized Bispecific Antibodies Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humanized Bispecific Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Humanized Bispecific Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humanized Bispecific Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Humanized Bispecific Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Humanized Bispecific Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Humanized Bispecific Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Humanized Bispecific Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Humanized Bispecific Antibodies Market Size, 2020 VS 2024 VS 2031
1.3 Global Humanized Bispecific Antibodies Market Size Estimates and Forecasts (2020-2031)
1.4 Global Humanized Bispecific Antibodies Sales Estimates and Forecasts (2020-2031)
1.5 Global Humanized Bispecific Antibodies Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Humanized Bispecific Antibodies Market Dynamics
2.1 Humanized Bispecific Antibodies Industry Trends
2.2 Humanized Bispecific Antibodies Industry Drivers
2.3 Humanized Bispecific Antibodies Industry Opportunities and Challenges
2.4 Humanized Bispecific Antibodies Industry Restraints
3 Humanized Bispecific Antibodies Market by Manufacturers
3.1 Global Humanized Bispecific Antibodies Revenue by Manufacturers (2020-2025)
3.2 Global Humanized Bispecific Antibodies Sales by Manufacturers (2020-2025)
3.3 Global Humanized Bispecific Antibodies Average Sales Price by Manufacturers (2020-2025)
3.4 Global Humanized Bispecific Antibodies Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Humanized Bispecific Antibodies Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Humanized Bispecific Antibodies Manufacturers, Product Type & Application
3.7 Global Humanized Bispecific Antibodies Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Humanized Bispecific Antibodies Market CR5 and HHI
3.8.2 Global Top 5 and 10 Humanized Bispecific Antibodies Players Market Share by Revenue in 2024
3.8.3 2024 Humanized Bispecific Antibodies Tier 1, Tier 2, and Tier 3
4 Humanized Bispecific Antibodies Market by Type
4.1 Humanized Bispecific Antibodies Type Introduction
4.1.1 IgG-like Double Antibody
4.1.2 Fragmented Dual Antibody (FAD)
4.1.3 Others
4.2 Global Humanized Bispecific Antibodies Sales by Type
4.2.1 Global Humanized Bispecific Antibodies Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Humanized Bispecific Antibodies Sales by Type (2020-2031)
4.2.3 Global Humanized Bispecific Antibodies Sales Market Share by Type (2020-2031)
4.3 Global Humanized Bispecific Antibodies Revenue by Type
4.3.1 Global Humanized Bispecific Antibodies Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Humanized Bispecific Antibodies Revenue by Type (2020-2031)
4.3.3 Global Humanized Bispecific Antibodies Revenue Market Share by Type (2020-2031)
5 Humanized Bispecific Antibodies Market by Application
5.1 Humanized Bispecific Antibodies Application Introduction
5.1.1 Infectious Disease Control
5.1.2 Immune Disease Treatment
5.1.3 Oncology Treatment
5.1.4 Others
5.2 Global Humanized Bispecific Antibodies Sales by Application
5.2.1 Global Humanized Bispecific Antibodies Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Humanized Bispecific Antibodies Sales by Application (2020-2031)
5.2.3 Global Humanized Bispecific Antibodies Sales Market Share by Application (2020-2031)
5.3 Global Humanized Bispecific Antibodies Revenue by Application
5.3.1 Global Humanized Bispecific Antibodies Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Humanized Bispecific Antibodies Revenue by Application (2020-2031)
5.3.3 Global Humanized Bispecific Antibodies Revenue Market Share by Application (2020-2031)
6 Global Humanized Bispecific Antibodies Sales by Region
6.1 Global Humanized Bispecific Antibodies Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Humanized Bispecific Antibodies Sales by Region (2020-2031)
6.2.1 Global Humanized Bispecific Antibodies Sales by Region (2020-2025)
6.2.2 Global Humanized Bispecific Antibodies Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Humanized Bispecific Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Humanized Bispecific Antibodies Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Humanized Bispecific Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Humanized Bispecific Antibodies Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Humanized Bispecific Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Humanized Bispecific Antibodies Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Humanized Bispecific Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Humanized Bispecific Antibodies Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Humanized Bispecific Antibodies Revenue by Region
7.1 Global Humanized Bispecific Antibodies Revenue by Region
7.1.1 Global Humanized Bispecific Antibodies Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Humanized Bispecific Antibodies Revenue by Region (2020-2025)
7.1.3 Global Humanized Bispecific Antibodies Revenue by Region (2026-2031)
7.1.4 Global Humanized Bispecific Antibodies Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Humanized Bispecific Antibodies Revenue (2020-2031)
7.2.2 North America Humanized Bispecific Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Humanized Bispecific Antibodies Revenue (2020-2031)
7.3.2 Europe Humanized Bispecific Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Humanized Bispecific Antibodies Revenue (2020-2031)
7.4.2 Asia-Pacific Humanized Bispecific Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Humanized Bispecific Antibodies Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Humanized Bispecific Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Tuowei Biotechnology
8.1.1 Tuowei Biotechnology Comapny Information
8.1.2 Tuowei Biotechnology Business Overview
8.1.3 Tuowei Biotechnology Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Tuowei Biotechnology Humanized Bispecific Antibodies Product Portfolio
8.1.5 Tuowei Biotechnology Recent Developments
8.2 Genor Biopharma
8.2.1 Genor Biopharma Comapny Information
8.2.2 Genor Biopharma Business Overview
8.2.3 Genor Biopharma Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Genor Biopharma Humanized Bispecific Antibodies Product Portfolio
8.2.5 Genor Biopharma Recent Developments
8.3 Hansoh Pharmaceutical
8.3.1 Hansoh Pharmaceutical Comapny Information
8.3.2 Hansoh Pharmaceutical Business Overview
8.3.3 Hansoh Pharmaceutical Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Hansoh Pharmaceutical Humanized Bispecific Antibodies Product Portfolio
8.3.5 Hansoh Pharmaceutical Recent Developments
8.4 Doma Biopharmaceutical
8.4.1 Doma Biopharmaceutical Comapny Information
8.4.2 Doma Biopharmaceutical Business Overview
8.4.3 Doma Biopharmaceutical Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Doma Biopharmaceutical Humanized Bispecific Antibodies Product Portfolio
8.4.5 Doma Biopharmaceutical Recent Developments
8.5 Dizal Pharma
8.5.1 Dizal Pharma Comapny Information
8.5.2 Dizal Pharma Business Overview
8.5.3 Dizal Pharma Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Dizal Pharma Humanized Bispecific Antibodies Product Portfolio
8.5.5 Dizal Pharma Recent Developments
8.6 Betta Pharmaceuticals
8.6.1 Betta Pharmaceuticals Comapny Information
8.6.2 Betta Pharmaceuticals Business Overview
8.6.3 Betta Pharmaceuticals Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Betta Pharmaceuticals Humanized Bispecific Antibodies Product Portfolio
8.6.5 Betta Pharmaceuticals Recent Developments
8.7 Biocytogen Co., Ltd.
8.7.1 Biocytogen Co., Ltd. Comapny Information
8.7.2 Biocytogen Co., Ltd. Business Overview
8.7.3 Biocytogen Co., Ltd. Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Biocytogen Co., Ltd. Humanized Bispecific Antibodies Product Portfolio
8.7.5 Biocytogen Co., Ltd. Recent Developments
8.8 EpimAb Biotherapeutics
8.8.1 EpimAb Biotherapeutics Comapny Information
8.8.2 EpimAb Biotherapeutics Business Overview
8.8.3 EpimAb Biotherapeutics Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 EpimAb Biotherapeutics Humanized Bispecific Antibodies Product Portfolio
8.8.5 EpimAb Biotherapeutics Recent Developments
8.9 Allist
8.9.1 Allist Comapny Information
8.9.2 Allist Business Overview
8.9.3 Allist Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Allist Humanized Bispecific Antibodies Product Portfolio
8.9.5 Allist Recent Developments
8.10 MacroGenics
8.10.1 MacroGenics Comapny Information
8.10.2 MacroGenics Business Overview
8.10.3 MacroGenics Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 MacroGenics Humanized Bispecific Antibodies Product Portfolio
8.10.5 MacroGenics Recent Developments
8.11 Johnson & Johnson
8.11.1 Johnson & Johnson Comapny Information
8.11.2 Johnson & Johnson Business Overview
8.11.3 Johnson & Johnson Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Johnson & Johnson Humanized Bispecific Antibodies Product Portfolio
8.11.5 Johnson & Johnson Recent Developments
8.12 AstraZeneca
8.12.1 AstraZeneca Comapny Information
8.12.2 AstraZeneca Business Overview
8.12.3 AstraZeneca Humanized Bispecific Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 AstraZeneca Humanized Bispecific Antibodies Product Portfolio
8.12.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Humanized Bispecific Antibodies Value Chain Analysis
9.1.1 Humanized Bispecific Antibodies Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Humanized Bispecific Antibodies Production Mode & Process
9.2 Humanized Bispecific Antibodies Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Humanized Bispecific Antibodies Distributors
9.2.3 Humanized Bispecific Antibodies Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.